EUZ Stock Overview
Manufactures and sells isotope technology components worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EUZ from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Eckert & Ziegler SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €44.94 |
| 52 Week High | €49.60 |
| 52 Week Low | €32.50 |
| Beta | 1.32 |
| 1 Month Change | 18.33% |
| 3 Month Change | 1.72% |
| 1 Year Change | 13.31% |
| 3 Year Change | -53.81% |
| 5 Year Change | -2.73% |
| Change since IPO | 586.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| EUZ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -3.0% | -2.2% | -1.1% |
| 1Y | 13.3% | -7.2% | 8.1% |
Return vs Industry: EUZ exceeded the German Medical Equipment industry which returned -7.2% over the past year.
Return vs Market: EUZ exceeded the German Market which returned 8.1% over the past year.
Price Volatility
| EUZ volatility | |
|---|---|
| EUZ Average Weekly Movement | 5.7% |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: EUZ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: EUZ's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2024 | 1,143 | Harald Hasselmann | www.ezag.com |
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; ophthalmological products; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services.
Eckert & Ziegler SE Fundamentals Summary
| EUZ fundamental statistics | |
|---|---|
| Market cap | €943.88m |
| Earnings (TTM) | €35.90m |
| Revenue (TTM) | €277.72m |
26.3x
P/E Ratio3.4x
P/S RatioIs EUZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EUZ income statement (TTM) | |
|---|---|
| Revenue | €277.72m |
| Cost of Revenue | €144.30m |
| Gross Profit | €133.43m |
| Other Expenses | €97.52m |
| Earnings | €35.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 27, 2025
| Earnings per share (EPS) | 1.72 |
| Gross Margin | 48.04% |
| Net Profit Margin | 12.93% |
| Debt/Equity Ratio | 8.6% |
How did EUZ perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield3%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 00:02 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eckert & Ziegler SE is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adrian Kowollik | Dr. Kalliwoda Research |
| Alexander Galitsa | Hauck Aufhäuser Investment Banking |
| Simon Keller | Hauck Aufhäuser Investment Banking |